Literature DB >> 35978683

Application of Selective SMARCA2/4 PROTAC for Mutant Cancer Therapy.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2022        PMID： 35978683      PMCID： PMC9377322          DOI： 10.1021/acsmedchemlett.2c00316

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

1.  SMARCA2 is regulated by NORFA-miR-29c, a novel pathway that controls granulosa cell apoptosis and is related to female fertility.

Authors:  Xing Du; Lu Liu; Wangjun Wu; Pinghua Li; Zengxiang Pan; Lifan Zhang; Jiying Liu; Qifa Li
Journal:  J Cell Sci       Date:  2020-12-07       Impact factor: 5.285

Review 2.  Clinical considerations for the design of PROTACs in cancer.

Authors:  Cristina Nieto-Jiménez; Esther Cabañas Morafraile; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Mol Cancer       Date:  2022-03-07       Impact factor: 27.401

3.  SWI/SNF chromatin remodeler complex within the reward pathway is required for behavioral adaptations to stress.

Authors:  François Tronche; Sébastien Parnaudeau; Abdallah Zayed; Camille Baranowski; Anne-Claire Compagnion; Cécile Vernochet; Samah Karaki; Romain Durand-de Cuttoli; Estefani Saint-Jour; Soumee Bhattacharya; Fabio Marti; Peter Vanhoutte; Moshe Yaniv; Philippe Faure; Jacques Barik; Laurence Amar
Journal:  Nat Commun       Date:  2022-04-04       Impact factor: 17.694

Review 4.  BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.

Authors:  Ningning Yan; Sanxing Guo; Huixian Zhang; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

Review 5.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.